PRLD Prelude Therapeutics Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1678660 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY105.4%
TTM net income YoY52.3%
TTM EPS YoY59.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-283.9%
Net margin-247.1%
FCF margin-129.6%
EBITDA margin-277.0%
Returns
ROE-58.4%
ROA-39.5%
ROIC (approx.)-86.6%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets29.3%
Debt / equity0.00x
Current ratio4.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-18.8%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.65M | $5.70M | $4.58M | $5.64M | $6.50M | $0 | $0 | $4.00M |
| R&D expense | $14.83M | $16.13M | $13.60M | $17.99M | $21.71M | $25.78M | $28.82M | $31.62M |
| SG&A expense | $5.08M | $5.03M | $5.16M | $5.00M | $5.21M | $6.41M | $5.79M | $6.21M |
| Operating income | -$14.27M | -$15.45M | -$14.18M | -$17.35M | -$20.42M | -$32.19M | -$34.61M | -$33.83M |
| Net income | -$12.54M | -$13.92M | -$10.38M | -$16.46M | -$19.73M | -$31.23M | -$32.09M | -$28.73M |
| EBITDA | -$13.92M | -$15.10M | -$13.79M | -$16.93M | -$19.99M | -$31.76M | -$34.17M | -$33.34M |
| EPS (basic) | -0.12 | -0.14 | -0.13 | — | -0.26 | -0.41 | -0.42 | — |
| EPS (diluted) | -0.12 | -0.14 | -0.13 | — | -0.26 | -0.41 | -0.42 | — |
| Weighted avg. shares (diluted) | 103.09M | 98.39M | 82.52M | — | 76.13M | 75.99M | 75.99M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $23.41M | $26.33M | $21.76M | $35.26M | $47.53M | $25.75M | $40.27M | $12.47M |
| Short-term investments | $116.59M | $125.43M | $59.80M | $67.96M | $7.42M | $47.46M | $58.80M | $121.14M |
| Current assets | $142.43M | $154.90M | $84.59M | $105.69M | $58.33M | $76.88M | $102.40M | $135.90M |
| PP&E, net | $4.06M | $4.40M | $4.72M | $5.11M | $5.53M | $5.96M | $6.39M | $6.77M |
| Total assets | $175.49M | $189.36M | $119.64M | $141.31M | $94.75M | $114.92M | $141.26M | $175.51M |
| Current liabilities | $33.93M | $38.04M | $41.72M | $52.99M | $18.19M | $20.91M | $19.79M | $25.64M |
| Total liabilities | $51.35M | $55.63M | $59.46M | $72.68M | $36.22M | $39.08M | $38.08M | $44.06M |
| Shareholders' equity | $124.14M | $133.73M | $60.18M | $68.64M | $58.53M | $75.84M | $103.18M | $131.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.78M | -$15.57M | -$21.68M | $23.12M | -$19.11M | -$26.07M | -$34.23M | -$20.74M |
| Capital expenditure | $35,000 | $0 | $0 | $0 | $0 | $20,000 | $47,000 | $53,000 |
| Free cash flow | -$13.81M | -$15.57M | -$21.68M | $23.12M | -$19.11M | -$26.09M | -$34.28M | -$20.80M |
| Investing cash flow | $9.02M | -$65.50M | $8.50M | -$60.34M | $40.09M | $11.52M | $62.19M | $22.12M |
| Financing cash flow | $1.17M | $85.82M | -$314,000 | $24.94M | -$5,000 | $37,000 | -$160,000 | -$34,000 |
| Depreciation & amortization | $341,000 | $353,000 | $391,000 | $418,000 | $425,000 | $433,000 | $435,000 | $489,000 |
| Stock-based compensation | $2.03M | $2.03M | $2.00M | $1.84M | $2.42M | $3.81M | $3.83M | $3.77M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.